Guangzhou DeepMed Medical Technology Co., Ltd. has recently declared the successful closure of its Series B funding round, amassing nearly RMB 100 million. This financing endeavor was co-led by Powerful Capital and Shengshi Investment, with additional support from Chenhui Venture Capital, Chengshu Investment, Dongguan Science and Technology Innovation, and the existing shareholder, Wondfo Venture Valley. Qiangyun Capital has retained its role as the exclusive financial advisor. This achievement represents DeepMed's third funding round within a span of 15 months, with the capital earmarked for expediting multi-indication clinical trials, product registration processes, and expanding its footprint in both domestic and international markets.

DeepMed's flagship offering, FUNZAR, stands as the world's pioneering modular universal microscopic surgical robot. Leveraging its groundbreaking MRCM (Universal Microscopic Configuration) technology, it facilitates sub-micron precision surgeries. The robot's prowess was showcased when it adeptly performed a 0.1-millimeter mouse tail artery anastomosis during the Super Microsurgery Human-Machine Competition. Presently, multi-indication, multi-center clinical trials are concurrently underway at several prestigious Grade A Tertiary Hospitals, with enrollment for the initial indication approaching completion.

Furthermore, FUNZAR has achieved notable milestones, including executing the world's first microscopic surgical robot-assisted direct bypass surgery for moyamoya disease cerebral revascularization and the world's inaugural spermatic vein reflux vessel reconstruction shunt procedure. It has also gained entry into the National Innovative Medical Device Green Channel. The company's core team is committed to foundational innovation, and this latest funding round has garnered widespread acclaim from all investors. All stakeholders are bullish on its technological edge, clinical advancements, and commercialization prospects, anticipating its rise as a frontrunner in the microscopic surgical robot arena and its role in propelling the global expansion of Chinese-originated microsurgical equipment.